Celldex Therapeutics, Inc. (NASDAQ:CLDX) Files An 8-K Results of Operations and Financial Condition

39

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.


Celldex Therapeutics, Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Celldex Reports Third Quarter 2017 Results HAMPTON,…
To view the full exhibit click here

About Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company’s pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

An ad to help with our costs